Page last updated: 2024-08-17

spironolactone and cilazapril, anhydrous

spironolactone has been researched along with cilazapril, anhydrous in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (83.33)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amit, M; Berla, M; Kedar, Y; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I	1
Asai, M; Fukuda, S; Hayashi, M; Kawachi, H; Marumo, T; Monkawa, T; Saruta, T; Shimizu, F; Tsuji, M; Yoshino, J	1
Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L	1
Aleksandrowicz, E; Larczyński, W; Lysiak-Szydlowska, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L	1
Knap, N; Larczynski, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Wozniak, M	1
Ding, JL; Hao, JB; Hao, LR; Ren, LS; Zhang, L	1

Trials

4 trial(s) available for spironolactone and cilazapril, anhydrous

Article	Year
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:5 Topics: Aged; Albuminuria; Blood Pressure; Cilazapril; Creatinine; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypertension; Middle Aged; Mineralocorticoid Receptor Antagonists; Prospective Studies; Spironolactone	2004
Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney. Kidney international, 2007, Volume: 72, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cilazapril; Cross-Over Studies; Drug Therapy, Combination; Humans; Mineralocorticoid Receptor Antagonists; Nephritis, Interstitial; Renin-Angiotensin System; Spironolactone; Telmisartan	2007
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 52, Issue:3 Topics: Acetylglucosaminidase; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Chronic Disease; Cilazapril; Collagen Type III; Cross-Over Studies; Disease Progression; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Potassium; Proteinuria; Renin-Angiotensin System; Spironolactone; Telmisartan	2008
Spironolactone attenuates oxidative stress in patients with chronic kidney disease. Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:5 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Benzimidazoles; Benzoates; Chronic Disease; Cilazapril; Creatinine; Cross-Over Studies; Dinoprost; Diuretics; Female; Humans; Hydrochlorothiazide; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Spironolactone; Telmisartan	2008

Other Studies

2 other study(ies) available for spironolactone and cilazapril, anhydrous

Article	Year
Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:12 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies, Monoclonal; Blood Pressure; Cilazapril; Drug Therapy, Combination; Fibrosis; Glomerulonephritis, Membranoproliferative; Kidney; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Proteinuria; Rats; Rats, Wistar; Spironolactone; Thy-1 Antigens	2004
The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:8 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Cilazapril; Dialysis Solutions; Disease Models, Animal; Drug Therapy, Combination; Lymphocytes; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Fibrosis; Peritoneum; Peritonitis; Random Allocation; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Transforming Growth Factor beta1	2014

Article

Year

Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis.

Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:12

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies, Monoclonal; Blood Pressure; Cilazapril; Drug Therapy, Combination; Fibrosis; Glomerulonephritis, Membranoproliferative; Kidney; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Proteinuria; Rats; Rats, Wistar; Spironolactone; Thy-1 Antigens

2004

The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.

Laboratory investigation; a journal of technical methods and pathology, 2014, Volume: 94, Issue:8

Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Cilazapril; Dialysis Solutions; Disease Models, Animal; Drug Therapy, Combination; Lymphocytes; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Fibrosis; Peritoneum; Peritonitis; Random Allocation; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Transforming Growth Factor beta1

2014